Market Overview:
The global nivolumab drugs market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer, rising demand for targeted therapies, and growing investments by pharmaceutical companies in R&D activities. Based on type, the global nivolumab drugs market is segmented into 10ml, 4ml, and 24ml segments. The 10ml segment is expected to account for the largest share of the global nivolumab drugs market in 2018. This segment is also projected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. Based on application, the global nivolumab drugs market is divided into retail pharmacy, hospital pharmacy, and other segments.
Product Definition:
Nivolumab is a human monoclonal antibody that binds to PD-1, and blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
10ml:
Nivolumab is a human monoclonal antibody that interferes with the cell signaling pathway. It has been approved by the FDA for treatment of non-small cell lung cancer (NSCLC), but it has also shown efficacy in other indications such as rheumatoid arthritis, Crohn's disease, and psoriasis.
4ml:
4ml is the smallest volume unit of a medicine and it means that one dose of the given medicine contains 0.004 ml or 4 microliters. The size of 4ml vial is very small as compared to other pharmaceutical products such as ampoules, bottles, and syringes which are available in market with different sizes.
Application Insights:
The other application segment includes research institutes, clinical trials and government programs. The retail pharmacy was the largest application segment in 2017 owing to growing awareness about health issues among older population. According to a study published by the CDC in September 2016, nearly 50% of adults aged 65 years or above had at least two chronic conditions including high blood pressure and diabetes. Growing geriatric population is one of the major drivers for nivolumab drugs demand from hospital pharmacies as they are more prone to various diseases such as cancer, heart diseases and respiratory problems due to which they require regular medication.
Hospital pharmacies have higher stocking density than their retail counterparts as these facilities cater bulk orders of medicines that are required for large patient groups or multiple patients at a time which results in higher revenue generation for companies manufacturing these drugs.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors contributing to its growth. Moreover, growing target population base with high unmet clinical needs is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising healthcare expenditure and improving economic conditions in emerging countries such as China and India. Furthermore, an increase in public & private partnerships between governments & pharmaceutical companies for developing novel drugs will also boost regional growth over the next eight years.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the global nivolumab drugs market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the United States in 2017. This number is expected to rise significantly in the coming years due to factors such as aging population and rising pollution levels.
- Rising demand for targeted therapies: The growing demand for targeted therapies is another major driver for the global nivolumab drugs market. Nivolumab belongs to a class of drugs known as checkpoint inhibitors, which work by blocking proteins that help tumors evade detection by the immune system. As a result, they are increasingly being used as first-line treatments for various types of cancers.
- Technological advancements: The advent of next-generation sequencing (NGS) technologies has led to significant advances in our understanding of tumor biology and helped identify new therapeutic targets for nivolumab therapy. This has resulted in an increase in R&D spending on novel checkpoint inhibitors and is likely to drive market growth over the forecast period..
Scope Of The Report
Report Attributes
Report Details
Report Title
Nivolumab Drugs Market Research Report
By Type
10ml, 4ml, 24ml
By Application
Retail Pharmacy, Hospital Pharmacy, Other
By Companies
Bristol-Myers Squibb, Ono Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Nivolumab Drugs Market Report Segments:
The global Nivolumab Drugs market is segmented on the basis of:
Types
10ml, 4ml, 24ml
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Retail Pharmacy, Hospital Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Ono Pharmaceutical
Highlights of The Nivolumab Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10ml
- 4ml
- 24ml
- By Application:
- Retail Pharmacy
- Hospital Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nivolumab Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nivolumab is a type of cancer drug that blocks the growth of tumor cells. It is approved to treat advanced melanoma, renal cell carcinoma, and non-small cell lung cancer.
Some of the major players in the nivolumab drugs market are Bristol-Myers Squibb, Ono Pharmaceutical.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Nivolumab Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Nivolumab Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Nivolumab Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Nivolumab Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Nivolumab Drugs Market Size & Forecast, 2020-2028 4.5.1 Nivolumab Drugs Market Size and Y-o-Y Growth 4.5.2 Nivolumab Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 10ml
5.2.2 4ml
5.2.3 24ml
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Retail Pharmacy
6.2.2 Hospital Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Nivolumab Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Nivolumab Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 10ml
9.6.2 4ml
9.6.3 24ml
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Retail Pharmacy
9.10.2 Hospital Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 10ml
10.6.2 4ml
10.6.3 24ml
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Retail Pharmacy
10.10.2 Hospital Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 10ml
11.6.2 4ml
11.6.3 24ml
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Retail Pharmacy
11.10.2 Hospital Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 10ml
12.6.2 4ml
12.6.3 24ml
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Retail Pharmacy
12.10.2 Hospital Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 10ml
13.6.2 4ml
13.6.3 24ml
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Retail Pharmacy
13.10.2 Hospital Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Nivolumab Drugs Market: Competitive Dashboard
14.2 Global Nivolumab Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb
14.3.2 Ono Pharmaceutical